Organisation paid for research Program year 2025 Source: CMS Open Payments

Cei Physicians PSC Inc

Neither a doctor nor a teaching hospital

Research payments

$1,446,190

1,048 payments

Through program year 2025, Cei Physicians PSC Inc is reported as receiving $1,446,190 in research payments, across 1,048 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$183,083	25
2024	Research	$304,756	101
2023	Research	$283,961	93
2022	Research	$208,699	109
2021	Research	$257,987	412
2020	Research	$107,127	48
2019	Research	$100,576	260

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $599,328 41 payments
Alcon Research LLC $567,305 987 payments
Biogen, Inc. $179,896 7 payments
Ocular Therapeutix, Inc. $51,099 2 payments
Spark Therapeutics, Inc. $48,563 11 payments

Studies the money was for Research payments · program years 2019–2025

Phase IIa Geographic Atrophy Study $386,155 17 payments
Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $209,478 491 payments
An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) $137,795 3 payments
Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix $111,830 105 payments
PMCF Evaluation of Clareon Vivity and Vivity Toric $103,329 63 payments
Post Approval Study of the AcrySof IQ ReSTOR Toric IOL (Models SND1T3-T6) $100,576 260 payments
Phase 2 of Ro7171009 in Ga $87,150 6 payments
PH 2 Open Label Extension of Ahtra1 in Ga $75,360 9 payments
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $51,099 2 payments
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study $35,246 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.